News | September 23, 2024
DevCo completes strategic capital raise for investment in Medix Biochemica
The raised capital enables Medix Biochemica to continue execution of inorganic growth initiatives
The raised capital enables Medix Biochemica to continue execution of inorganic growth initiatives
This approval reflects company’s unwavering commitment that the quality assurance
Doses will be ready to ship to applicable European Union (EU) member states as soon as possible upon European Commission (EC) authorization
A multi-disciplinary team of senior physicians opted to use Zidebactam/Cefepime under compassionate use
Fermenta Biotech’s API manufacturing facility receives EU GMP compliance certificate
Professor G. D. Yadav is one of India’s most prolific and accomplished engineering-scientists, holding the prestigious National Science Chair from the Government of India
Wacker Biotech will manufacture the active ingredients of MinervaX’s novel vaccine candidate
The award is for development of Nafithromycin, which is the first ever multi-drug resistant pathogen active respiratory antibiotic for the treatment of Community-Acquired Bacterial Pneumonia
Target identification will commence on 17 September 2024, following the timeline provided in the campaign guidelines
GPCB has also asked to submit a bank guarantee of Rs. 2, 00,000 for compliance assurance at the time of revocation and has also ordered to deposit interim environment damage compensation amount
Subscribe To Our Newsletter & Stay Updated
